Articles Vol. 67 No. 10 25/10/2026

CLASCOTERONE TRONG ĐIỀU TRỊ MỤN TRỨNG CÁ: BẰNG CHỨNG LÂM SÀNG VÀ TRIỂN VỌNG ỨNG DỤNG TẠI VIỆT NAM

Pham Ho Thanh Thanh, Huynh Huyen Chau
DOI: 10.52163/yhc.v67i10.6898
0 Views
0 Downloads
Abstract

Objective: To synthesize current clinical evidence on clascoterone for acne vulgaris and discuss its potential application in Vietnam.

Search methods and review: Narrative review. PubMed/MEDLINE, Google Scholar, and Cochrane Library were searched (January 2011–May 2026) using the terms clascoterone, cortexolone 17α-propionate, and acne vulgaris. Eligible sources included phase III trials, systematic reviews/meta-analyses, international guidelines, and FDA regulatory documents.

Results: Ten publications were included. Two phase III trials (n = 1,440) showed treatment success rates of 18.4–20.3% with clascoterone versus 6.5–9.0% with vehicle (p < 0.001) [3]. A network meta-analysis of 7 RCTs found OR = 2.44 (95% CI 1.12–5.30) versus vehicle, not a direct comparison with spironolactone [6]. The 2024 AAD guideline issued a conditional recommendation for patients aged 9 years and older; the FDA-approved indication is limited to patients 12 years and older [3,8]. The drug currently has no confirmed marketing authorization in Vietnam.

Conclusion: Clascoterone is effective and well tolerated in vehicle-controlled trials. Its use in Vietnam should be considered pending verification of regulatory status, cost-effectiveness data, and guideline updates.

Keywords
clascoterone; acne vulgaris; topical antiandrogen
References
[1]
1. Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754. https://doi.org/10.1038/s41598-020-62715-3 Google Scholar
[2]
2. U.S. Food and Drug Administration. NDA 213433 approval letter for Winlevi (clascoterone) cream, 1%. Silver Spring, MD: FDA Center for Drug Evaluation and Research; August 26, 2020. Google Scholar
[3]
3. Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621-630. https://doi.org/10.1001/jamadermatol.2020.0465 Google Scholar
[4]
4. Bộ Y tế Việt Nam. Hướng dẫn chẩn đoán và điều trị các bệnh da liễu. Hà Nội: Nhà Xuất bản Y học; 2023. Google Scholar
[5]
5. Rosette C, Agan FJ, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019;18(5):412-418. Google Scholar
[6]
6. Basendwh MA, Alharbi AA, Bukhamsin SA, Abdulwahab RA, Alaboud SA. The efficacy of topical clascoterone versus systematic spironolactone for treatment of acne vulgaris: a systematic review and network meta-analysis. PLoS One. 2024;19(5):e0298155. https://doi.org/10.1371/journal.pone.0298155 Google Scholar
[7]
7. Bhatia N, Eichenfield LF, Mazzetti A, Moro L, Squittieri N, Hebert AA. Hypothalamic-pituitary-adrenal axis response in patients with acne vulgaris treated with clascoterone. J Drugs Dermatol. 2024;23(6):433-437. https://doi.org/10.36849/JDD.7997 Google Scholar
[8]
8. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. https://doi.org/10.1016/j.jaad.2023.12.017 Google Scholar
[9]
9. European Medicines Agency (EMA). Approval of the marketing authorisation for Winlevi (clascoterone). EMA/277213/2025, EMEA/H/C/006138. Amsterdam: EMA; 26 August 2025. Google Scholar
[10]
10. Eichenfield LF, Hebert AA, Stein Gold L, Cartwright M, Moro L, Han J, Squittieri N, Mazzetti A. Long-term safety and efficacy of twice-daily topical clascoterone cream 1% in patients greater than or equal to 12 years of age with acne vulgaris. J Drugs Dermatol. 2023;22(8):810-816. https://doi.org/10.36849/jdd.7592 Google Scholar